Recombinant Drosophila orena Cecropin-C (CecC)

Definition and Overview

Recombinant Drosophila simulans Cecropin-C (CecC) is a bacterially expressed or baculovirus-derived version of the endogenous Cecropin-C peptide, a key component of the insect immune response. It is engineered for research applications to study its antimicrobial properties and mechanisms of action . The mature peptide is generated by removing the signal sequence from the precursor protein, resulting in a 39-amino acid active peptide .

Production and Purification

Recombinant CecC is produced via baculovirus expression in insect cell cultures, followed by affinity chromatography and refolding steps to ensure proper conformation . Key production notes include:

• Storage: -20°C for short-term; -80°C with 50% glycerol for long-term stability .

• Reconstitution: Solubilized in sterile deionized water at 0.1–1.0 mg/mL .

• Activity Validation: Confirmed via antimicrobial assays against model pathogens like Escherichia coli and Staphylococcus aureus .

Antimicrobial Activity

• Gram-Negative Bacteria: CecC disrupts bacterial membranes via electrostatic interactions with lipopolysaccharides (LPS), leading to cell lysis . In Drosophila, Cecropins (including CecC) are critical for controlling infections by Enterobacter cloacae and Providencia heimbachae, especially when other AMPs are absent .

• Fungi: CecC exhibits fungicidal activity by permeabilizing fungal membranes, though this function is less characterized than its antibacterial effects .

Immune Response Dynamics

• CecC is induced during metamorphosis and systemic infections, with expression peaking in larval stages and immunized adults .

• In Drosophila, Cecropins act synergistically with other AMPs like Drosocin to enhance pathogen clearance, though redundancy among AMPs often masks their individual contributions .

Research Applications

Recombinant CecC is primarily used in:

1. Mechanistic Studies: Investigating pore formation in bacterial membranes .

2. Immune Response Modeling: Testing pathogen resistance in Drosophila AMP-deficient mutants (e.g., ΔAMP14 flies) .

3. Therapeutic Development: Serving as a template for designing synthetic antimicrobial agents .

Limitations and Future Directions

While recombinant CecC has proven valuable in basic research, its clinical potential is limited by:

• Species-Specific Activity: Efficacy in mammalian systems remains untested .

• Stability Issues: Requires cold storage and reconstitution protocols to maintain activity .
  Future studies could optimize delivery systems (e.g., nanoparticle encapsulation) and explore hybrid peptides combining CecC with mammalian AMPs .